How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation

Abstract

The clinical translation of promising products, technologies and interventions from the disciplines of nanomedicine and cell therapy has been slow and inefficient. In part, translation has been hampered by suboptimal research practices that propagate biases and hinder reproducibility. These include the publication of small and underpowered preclinical studies, suboptimal study design (in particular, biased allocation of experimental groups, experimenter bias and lack of necessary controls), the use of uncharacterized or poorly characterized materials, poor understanding of the relevant biology and mechanisms, poor use of statistics, large between-model heterogeneity, absence of replication, lack of interdisciplinarity, poor scientific training in study design and methods, a culture that does not incentivize transparency and sharing, poor or selective reporting, misaligned incentives and rewards, high costs of materials and protocols, and complexity of the developed products, technologies and interventions. In this Perspective, we discuss special manifestations of these problems in nanomedicine and in cell therapy, and describe mitigating strategies. Progress on reducing bias and enhancing reproducibility early on ought to enhance the translational potential of biomedical findings and technologies.

Gene Therapy in Cancer Treatment: Why Go Nano?

“…discusses the necessity of more thoughtful design of preclinical studies to potentiate the hypothesis for translation to the clinics [259]. According to the authors, the applied research practices result in biased and low reproducible preclinical studies, with poor design of the studies, poor characterization of the nanomaterials, incomplete studies of their biological effect, models heterogeneity and poor use of controls and statistics [259].…”

Emerging Technologies for Local Cancer Treatment

“…On this note, significant coordinated efforts are required for more robust preclinical study design to minimize bias, enhance reproducibility and maximize translational potential. [158] In terms of clinical testing, attention should be given to the design of clinical trials for local drug delivery systems, including refine selection of patient population, including those with inoperable tumors. Moreover, the heterogeneity and seemingly endless evolution of cancer demands comprehensive monitoring of response before, during, and after local treatment.…”

The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models In Vivo Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ

“…Preclinical studies in mouse models play an important role in supporting the clinical drug development process. However, there has been emerging awareness recently of limitations of the preclinical research endeavor in generating information that translates usefully into clinical practice (22,23). One significant issue is that much preclinical work is done using a relatively small number of well-studied models that fail to capture the heterogeneity of the human disease.…”